Predicting Fracture Risk in Patients Treated with Radiotherapy for Spinal Metastatic Disease

预测脊柱转移性疾病放射治疗患者的骨折风险

基本信息

  • 批准号:
    10002563
  • 负责人:
  • 金额:
    $ 66.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-25 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract We seek to improve the prediction of the risk of pathologic vertebral fracture (PVF) in patients who are treated with radiotherapy for bone metastases in the spine. Vertebral bone is the most frequent site of skeletal metastasis. Radiation therapy aims to palliate pain and reduce the risk of pathologic vertebral fracture. However, vertebral fractures are a common complication afflicting up to 39% of patients within 6 months after- radiotherapy. Clinical guidelines for estimating fracture risk remain subjective and suffer from low specificity and sensitivity. Improved assessment of fracture risk would facilitate selection of whether, how, and when to intervene prior to the occurrence of fractures. Such individualized prediction is not available in clinical practice. As part of our previous NIH grant, we have developed a computed tomography (CT) based structural analysis (CT-SAP) to successfully predict the failure of human spines with lytic defects. Based on these accomplishments, the objectives of this observational prospective study are threefold: 1) To test the performance of CT-SAP (providing a snapshot of bone structure and calcium content) and bone turnover markers (providing an indication of disease trajectory) for predicting the baseline risk of vertebral fractures in a cohort of patients treated with radiotherapy for spinal bone metastases. For this purpose, we will acquire the standard clinical CT and serum sample at the patient's radiotherapy planning. From the CT, we will derive individualized estimates of vertebral strength (CT-SAP) and vertebral loading to compute the loading / strength ratio for both treated and untreated vertebrae, and measure the value for markers for bone resorption and formation from the serum sample. We will test the independent association of the vertebral loading / strength ratio and marker value with the observed vertebral fractures within 6 months after treatment. This novel data will provide information on the effect of radiation and metastatic disease on the baseline and short term risk of vertebral fracture in this patient cohort. 2) To establish the performance of the spinal instability neoplastic score (SINS) for predicting the patient's risk of vertebral fracture within 6 months after treatment and test whether adding the load / strength ratio (CT-SAP) and bone turnover risk models, independently and combined, improves the model's performance. This will establish a new paradigm for individualized prediction of baseline risk for fracture in this patient cohort. 3) To test the established model performance for predicting the evolving risk of PVF within a 3 month interval by acquiring and analyzing the CT scans and serum samples collected at 3, 6, and 9 months after treatment as part of standard clinical care. This time period provides clinically meaningful guidelines for assessing the impact of a low vs. high risk of PVF to the health and quality of life of this infirm population with short life expectancy. Successful completion of this project will address a critical gap in our ability to individualize evaluation and management of these patients.
项目总结/摘要 我们试图提高对接受治疗的患者发生病理性椎体骨折(PVF)风险的预测 脊柱骨转移的放射治疗脊椎骨是最常见的骨骼损伤部位, 转移放射治疗的目的是减轻疼痛,降低病理性脊椎骨折的风险。 然而,椎骨骨折是一种常见的并发症,在术后6个月内困扰着高达39%的患者- 放疗评估骨折风险的临床指南仍然是主观的,特异性低 和敏感性。骨折风险评估的改善将有助于选择是否、如何以及何时 在骨折发生之前进行干预。这种个体化预测在临床实践中是不可用的。 作为我们以前NIH资助的一部分,我们开发了一种基于计算机断层扫描(CT)的结构 分析(CT-SAP),以成功地预测溶骨性缺陷的人类脊柱的失败。基于这些 这项观察性前瞻性研究的目标有三个方面:1)测试 CT-SAP的性能(提供骨结构和钙含量的快照)和骨转换 用于预测脊椎骨折基线风险的标志物(提供疾病轨迹的指示), 一组接受放射治疗的脊柱骨转移患者。为此,我们将收购 标准临床CT和患者放疗计划时的血清样本。从CT,我们将得出 椎体强度(CT-SAP)和椎体载荷的个体化估计,以计算载荷/ 治疗和未治疗椎骨的强度比,并测量骨标记物的值 从血清样品中吸收和形成。我们将测试脊椎的独立关联 载荷/强度比和标记值与治疗后6个月内观察到的椎体骨折。 该新数据将提供关于放射和转移性疾病对基线的影响的信息, 该患者队列中椎体骨折的短期风险。2)为了建立脊柱的性能 不稳定性肿瘤评分(SINS),用于预测患者在术后6个月内发生椎骨骨折的风险 治疗和测试是否加入负荷/强度比(CT-SAP)和骨转换风险模型, 独立和组合,提高了模型的性能。这将建立一个新的模式, 个体化预测该患者队列中骨折的基线风险。3)对建立的模型进行检验 通过获取和分析PVF的风险, 作为标准临床护理的一部分,在治疗后3、6和9个月收集CT扫描和血清样本。 该时间段为评估PVF低风险与高风险的影响提供了具有临床意义的指南 对这些预期寿命短的体弱人群的健康和生活质量的影响。成功完成本 该项目将解决我们对这些患者进行个性化评估和管理的能力方面的关键差距。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RON N ALKALAY其他文献

RON N ALKALAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RON N ALKALAY', 18)}}的其他基金

Predicting Fracture Risk in Patients Treated with Radiotherapy for Spinal Metastatic Disease
预测脊柱转移性疾病放射治疗患者的骨折风险
  • 批准号:
    10655309
  • 财政年份:
    2020
  • 资助金额:
    $ 66.2万
  • 项目类别:
Curating musculoskeletal CT data to enable the development of AI/ML approaches for analysis of clinical CT in patients with metastatic spinal disease
整理肌肉骨骼 CT 数据,以开发用于分析转移性脊柱疾病患者临床 CT 的 AI/ML 方法
  • 批准号:
    10593799
  • 财政年份:
    2020
  • 资助金额:
    $ 66.2万
  • 项目类别:
Predicting Fracture Risk in Patients Treated with Radiotherapy for Spinal Metastatic Disease
预测脊柱转移性疾病放射治疗患者的骨折风险
  • 批准号:
    10392406
  • 财政年份:
    2020
  • 资助金额:
    $ 66.2万
  • 项目类别:
Pre-Operative QCT Planning Protocol for Treating the Structural Deficiency of Spi
治疗 SPI 结构缺陷的术前 QCT 规划方案
  • 批准号:
    8066432
  • 财政年份:
    2008
  • 资助金额:
    $ 66.2万
  • 项目类别:
Pre-Operative QCT Planning Protocol for Treating the Structural Deficiency of Spi
治疗 SPI 结构缺陷的术前 QCT 规划方案
  • 批准号:
    7475488
  • 财政年份:
    2008
  • 资助金额:
    $ 66.2万
  • 项目类别:
Pre-Operative QCT Planning Protocol for Treating the Structural Deficiency of Spi
治疗 SPI 结构缺陷的术前 QCT 规划方案
  • 批准号:
    7651104
  • 财政年份:
    2008
  • 资助金额:
    $ 66.2万
  • 项目类别:
Pre-Operative QCT Planning Protocol for Treating the Structural Deficiency of Spi
治疗 SPI 结构缺陷的术前 QCT 规划方案
  • 批准号:
    7806546
  • 财政年份:
    2008
  • 资助金额:
    $ 66.2万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 66.2万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 66.2万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 66.2万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 66.2万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 66.2万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 66.2万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 66.2万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 66.2万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 66.2万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 66.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了